je.st
news
Tag: form
Coach Code of Conduct Form
2015-10-01 19:17:20| PortlandOnline
PDF Document, 425kbCategory: Team Registration Forms
Volunteer Background Check Form
2015-10-01 19:16:22| PortlandOnline
PDF Document, 453kbCategory: Team Registration Forms
Tags: form
check
background
volunteer
Registration Form
2015-10-01 19:14:27| PortlandOnline
PDF Document, 512kbCategory: Team Registration Forms
Tags: form
registration
registration form
form registration
Driver Permit Renewal Form
2015-10-01 17:37:27| PortlandOnline
PDF Document, 312kbCategory: Drivers
Tags: form
driver
permit
renewal
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
2015-10-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrixs oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] next »